Generate a tailored SOP for Dr. Michael Zalutsky. Improve your application with a focused, well-structured draft.
Dr. Michael Rod Zalutsky is a distinguished professor in Radiology, Biomedical Engineering, Pathology, and Radiation Oncology at Duke University. His research focuses on the development of innovative radioactive compounds that enhance the diagnosis and therapy of cancer. His laboratory employs site-specific radiohalogenation methods, which generally involve demetallation reactions. He utilizes imaging radionuclides such as I-123, I-124, and F-18, placing particular emphasis on the quantification of biochemical and physiological processes in living human tissues through positron emission tomography. Additionally, he explores the therapeutic potential of astatine-211, which emits alpha particles that provide highly cytotoxic effects against malignant cells while preserving surrounding healthy cells. Highlights from his recent work include the creation of protein and peptide radioiodination reagents that significantly decrease deiodination in vivo, and the demonstration of At-211 labeled monoclonal antibodies for effective treatment of neoplastic meningitis in rat models. Dr. Zalutsky's contributions to the field are underscored by his accolades, including the Aebersold Award from the Society of Nuclear Medicine in 2007 and the MERIT Award from the National Institutes of Health in 2005.
Department of Biomedical Engineering (MS program)